1
Total Mentions
1
Documents
0
Connected Entities
Name reference in documents
EFTA00843868
schizophrenia (Risperdal), diabetes (Invokana), psoriasis (Stela ra), migraines (Topamax), heart disease (Xarelto) and attention deficit disorder (Concerta). As of the start of this summer the company had to new drugs in the pipeline that might achieve more than a billion dollars in annual sales. Ads f
No connected entities